About Lakewood-Amedex Biotherapeutics (LABT) data
Data as of September 30, 2026.
Lakewood-Amedex Biotherapeutics (LABT) has 130.72K shares sold short as of the latest FINRA settlement report on September 30, 2026. Short interest has increased by 146.80% compared with the prior settlement. At the current average daily volume, covering all open short positions would take about 0.04 days (days to cover).
Frequently asked questions
What is the current short interest in LABT?
As of the latest FINRA settlement dated September 30, 2026, LABT had approximately 130,722 shares sold short. Short interest data is reported by FINRA twice per month.
How much does it cost to short LABT?
The latest borrow fee (cost to borrow) for LABT is 502.21% per year, based on IBKR data. Fees can change throughout the trading day as shares are borrowed and returned.
What is the days to cover ratio for LABT?
Days to cover for LABT is approximately 0.04 days. This estimates how many trading days it would take short sellers to buy back all outstanding short shares at the current average daily volume.
How many LABT shares failed to deliver?
On September 30, 2026, the latest settlement date in the SEC's fails-to-deliver data, 20,134 shares of LABT had failed to deliver, worth about $19.93K at the prior day's close (0.85% of shares outstanding). That is the balance still outstanding that day, not new fails. Fails come from long sales and delivery delays as well as short sales.
Is LABT a short squeeze candidate?
A squeeze needs shorts that are hard to close. LABT trades about 3,343,756 shares a day and would take roughly 0.04 days to unwind current short positions, at a current borrow fee of 502.21%. Higher days-to-cover and a rising borrow fee together are the setup to watch; neither alone is enough.